Scott Kinlay, MBBS, PhD

Adjunct Associate Professor, Medicine

Scott Kinlay
Division of Cardiology, VA Boston Healthcare System, 1400 VFW Parkway


Dr. Scott Kinlay is the Chief of Cardiology and Director of Vascular Medicine at the VA Boston Healthcare System, West Roxbury Campus. He is affiliated with Brigham and Women’s Hospital. He is currently licensed to practice medicine in Massachusetts.

Other Positions

  • Associate Professor, Medicine, Harvard Medical School
  • Chief, Cardiology, VA Boston Healthcare System
  • Director, Vascular Medicine, VA Boston Healthcare System


  • University of Sydney, MBBS
  • University of Newcastle, PhD


  • Published on 2/13/2024

    Kroshian G, Joseph J, Kinlay S, Peralta AO, Hoffmeister PS, Singh JP, Yuyun MF. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2024 Apr; 35(4):715-726. PMID: 38348517.

    Read at: PubMed
  • Published on 1/24/2024

    Shapeton AD, Kinlay S, Geahchan C, Ortoleva J. Perioperative Apixaban: Bleeding, Clotting, or Both? J Cardiothorac Vasc Anesth. 2024 Apr; 38(4):865-867. PMID: 38368165.

    Read at: PubMed
  • Published on 1/23/2024

    Belyayev L, Stock EM, Hattler B, Bakaeen FG, Kinlay S, Quin JA, Haime M, Biswas K, Zenati MA. Complete Coronary Revascularization and Outcomes in Patients Who Underwent Coronary Artery Bypass Grafting: Insights from The REGROUP Trial. Am J Cardiol. 2024 Apr 15; 217:127-135. PMID: 38266796.

    Read at: PubMed
  • Published on 11/17/2023

    Gikandi A, Habertheuer A, Stock EM, Hirji S, Kinlay S, Tsao A, Butala N, Biswas K, Zenati MA. Anatomical SYNTAX score and major adverse cardiac events following CABG in the REGROUP trial. J Cardiol. 2024 May; 83(5):348-350. PMID: 37977259.

    Read at: PubMed
  • Published on 10/19/2023

    Yuyun MF, Joseph J, Erqou SA, Kinlay S, Echouffo-Tcheugui JB, Peralta AO, Hoffmeister PS, Boden WE, Yarmohammadi H, Martin DT, Singh JP. Persistence of significant secondary mitral regurgitation post-cardiac resynchronization therapy and survival: a systematic review and meta-analysis : Mitral regurgitation and mortality post-CRT. Heart Fail Rev. 2024 Jan; 29(1):165-178. PMID: 37855988.

    Read at: PubMed
  • Published on 9/25/2023

    Kinlay S. Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication. JACC Cardiovasc Interv. 2023 Sep 25; 16(18):2335. PMID: 37758389.

    Read at: PubMed
  • Published on 9/4/2023

    Evans P, Sobieszczyk P, Eisenhauer AC, Ostrowski S, Todoran TM, Kinlay S. Risk of Mortality Related to Recurrent Limb Events After Endovascular Revascularization of the Superficial Femoral Artery for Peripheral Artery Disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) Study. Am J Cardiol. 2023 Oct 15; 205:425-430. PMID: 37666014.

    Read at: PubMed
  • Published on 7/28/2023

    Almarzooq ZI, Al-Roub NM, Kinlay S. Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk. Curr Opin Cardiol. 2023 Nov 01; 38(6):515-520. PMID: 37522805.

    Read at: PubMed
  • Published on 5/21/2023

    Kinlay S, Sobieszczyk P, Eisenhauer AC, Ostrowski S, Todoran TM. Patient and limb outcomes 10 years after endovascular revascularization of the superficial femoral artery for peripheral artery disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) study. Vasc Med. 2023 Aug; 28(4):290-298. PMID: 37211818.

    Read at: PubMed
  • Published on 1/16/2023

    Kinlay S, Young MM, Sherrod R, Gagnon DR. Long-Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study. J Am Heart Assoc. 2023 Jan 17; 12(2):e027055. PMID: 36645075.

    Read at: PubMed

View 152 more publications: View full profile at BUMC

View all profiles